News | Mammography | October 23, 2019

Cancer detection rates measure higher with DBT versus digital mammography regardless of tumor type, size or grade of cancer

Breast Tomosynthesis Increases Cancer Detection Over Digital Mammography

October 23, 2019 — Screening digital breast tomosynthesis (DBT) results in “significantly increased CDR [cancer detection rates]” compared to full-field digital mammography (FFDM), according to an ahead-of-print article in the March issue of the American Journal of Roentgenology (AJR).[1] DBT offered improved results irrespective of tumor type, size or grade of cancer.

Reviewing consecutive screening examinations performed between October 2012 and September 2014 at a large academic breast imaging practice, Pragya A. Dang, M.D., and researchers at Brigham and Women’s Hospital in Boston detected 61 cancers in the matched cohort of DBT (n = 9817) and FFDM (n = 14,180) examinations. 

CDR measured higher with DBT than with FFDM for invasive cancers (2.8 vs 1.3, p = 0.01), minimal cancers (2.4 vs 1.2, p = 0.03), estrogen receptor–positive invasive cancers (2.6 vs 1.1, p = 0.01), and node-negative invasive cancers (2.3 vs 1.1, p = 0.02.), respectively. 

However, the ratio of screen-detected invasive cancers to ductal carcinoma in situ on DBT (3.0) was not significantly different from that on FFDM (2.6) (p = 0.79).

Comparison of Overall Cancer Detection Rates of DBT and FFDM

Note—DCIS = ductal carcinoma in situ.

a —Values are rate per 1000 with number of examinations in parentheses.

b — Values in bold are statistically significant.

 

Where CDR were not statistically significant for DBT and FFDM, Dang noted, “We were likely underpowered to show a significant difference because of the smaller number of cancers in these subgroups. For instance, CDR of moderately and poorly differentiated invasive cancers, and for all cancer sizes detected with DBT, was nearly twice that of FFDM, even though it was not statistically significant.”

As Dang concluded, “our results suggest that integrating DBT into clinical practice may detect overall more cancers than does FFDM, for all tumor sub-types, grades, sizes and nodal statuses.”

For more information: www.ajronline.org

Reference

1. Dang P.A., Wang A., Senapati G.M., et al. Comparing Tumor Characteristics and Rates of Breast Cancers Detected by Screening Digital Breast Tomosynthesis and Full-Field Digital Mammography. American Journal of Roentgenology, published online Oct. 15, 2019. DOI: 10.2214/AJR.18.21060


Related Content

News | Breast Imaging

July 29, 2024 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced the ...

Time July 29, 2024
arrow
News | Breast Imaging

July 29, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced a ...

Time July 29, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiology Business

July 25, 2024 — The radiology gender gap is decreasing, but there remains work to be done, according to an editorial ...

Time July 25, 2024
arrow
Videos | Breast Imaging

Don't miss ITN's latest "One on One" video interview with AAWR Past President and American College of Radiology (ACR) ...

Time July 24, 2024
arrow
News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
News | Flat Panel Displays

July 17, 2024 — LG Electronics (LG) is accelerating its B2B medical device business, expanding its lineup of diagnostic ...

Time July 17, 2024
arrow
Feature | Imaging Technology News - ITN

Be sure to check out the latest digital edition of Imaging Technology News (ITN), featuring the Mobile C-arm Systems ...

Time July 11, 2024
arrow
News | Artificial Intelligence

July 9, 2024 — Lunit, a provider of Artificial Intelligence (AI)-powered solutions for cancer diagnostics and ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
Subscribe Now